High Growth Tech Stocks To Watch In September 2024
Over the last 7 days, the market has risen 1.8%, and over the past 12 months, it is up 32%, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high growth tech stocks that align with these robust trends can be crucial for investors looking to capitalize on market momentum.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
Super Micro Computer | 20.86% | 27.98% | ★★★★★★ |
Sarepta Therapeutics | 23.58% | 44.12% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.46% | 66.34% | ★★★★★★ |
Amicus Therapeutics | 20.32% | 62.37% | ★★★★★★ |
Clene | 71.89% | 60.05% | ★★★★★★ |
Travere Therapeutics | 26.68% | 68.80% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 252 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Capricor Therapeutics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Capricor Therapeutics, Inc. is a clinical-stage biotechnology company developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs, with a market cap of $321.57 million.
Operations: Capricor Therapeutics focuses on developing cell and exosome-based therapeutics, primarily targeting Duchenne muscular dystrophy (DMD). The company generates revenue from its biotechnology segment, amounting to $27.15 million.
Amidst a challenging landscape, Capricor Therapeutics stands out with its promising revenue growth forecast at 47.7% annually, significantly outpacing the US market average of 8.7%. Despite current unprofitability, the company is poised for substantial earnings expansion, projected at an impressive rate of 68.72% per year. Recent strategic moves include a pivotal agreement with Nippon Shinyaku for the European commercialization of deramiocel for Duchenne muscular dystrophy (DMD), potentially bolstering Capricor's financial position with an upfront payment of $20 million and up to $715 million in milestone payments. This deal not only underscores Capricor’s commitment to expanding its global footprint but also enhances its financial stability through a $15 million equity investment by Nippon Shinyaku at a premium, reflecting confidence in Capricor’s value proposition and future prospects in addressing critical unmet medical needs.
Dive into the specifics of Capricor Therapeutics here with our thorough health report.
Gain insights into Capricor Therapeutics' past trends and performance with our Past report.
ExlService Holdings
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ExlService Holdings, Inc. operates as a data analytics and digital operations solutions company in the United States and internationally, with a market cap of $5.97 billion.
Operations: ExlService Holdings generates revenue primarily from four segments: Analytics ($749.61 million), Insurance ($569.90 million), Healthcare ($106.48 million), and Emerging Business ($283.91 million). The company operates both in the United States and internationally, focusing on data analytics and digital operations solutions.
ExlService Holdings has demonstrated a robust commitment to innovation, evident from its recent integration of NVIDIA's full-stack AI technologies aimed at enhancing enterprise solutions in sectors like insurance and banking. This strategic move is expected to streamline operations and improve service delivery through advanced AI applications, reflecting a forward-thinking approach in leveraging technology. Financially, the company has shown solid performance with a 10.5% increase in sales to $448.37 million for Q2 2024 and an upward revision of its annual revenue forecast to between $1.805 billion and $1.830 billion, indicating confidence in sustained growth amidst competitive pressures. Additionally, ExlService's proactive share repurchase program, buying back shares worth $133.82 million recently, underscores its management's belief in the company’s intrinsic value and commitment to shareholder returns.
Navigate through the intricacies of ExlService Holdings with our comprehensive health report here.
Assess ExlService Holdings' past performance with our detailed historical performance reports.
Novanta
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally, with a market cap of approximately $6.36 billion.
Operations: Novanta Inc. generates revenue through three primary segments: Medical Solutions ($371.24 million), Robotics and Automation ($260.32 million), and Precision Medicine and Manufacturing ($268.30 million). The company operates internationally, focusing on advanced technology solutions across these sectors.
Novanta's strategic focus on R&D is evident with a significant allocation of resources, underscoring its commitment to innovation in high-tech sectors. This investment has facilitated a robust pipeline of advanced solutions, particularly in precision technology systems crucial for manufacturing and healthcare applications. Despite recent challenges reflected by a 19.1% dip in earnings last year, Novanta's revenue trajectory remains positive with an expected growth rate of 11.6% annually, outpacing the US market average of 8.7%. The company also projects an aggressive earnings growth forecast at 35.5% per year, signaling potential recovery and operational optimization ahead. These figures highlight Novanta’s resilience and strategic planning amidst market fluctuations and underline its potential as a key player in tech-driven sectors moving forward.
Click here and access our complete health analysis report to understand the dynamics of Novanta.
Examine Novanta's past performance report to understand how it has performed in the past.
Make It Happen
Gain an insight into the universe of 252 US High Growth Tech and AI Stocks by clicking here.
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Searching for a Fresh Perspective?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:CAPR NasdaqGS:EXLS and NasdaqGS:NOVT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com